OBJECTIVES: To perform an economic evaluation of prostate cancer (PC) treatment with luteinizing hormone-releasing hormone agonists (LHRH): leuprorelin (L), goserelin (G) and triptorelin (T) for Russian health care system. METHODS: A review was conducted to collect available evidence of the clinical efficacy and safety of L in comparison with G and T. Cost-minimization analysis was performed. Direct costs of treatment with studied drugs were considered for each option: cost for 1- year hormonal therapy in a hypothetical cohort of 100 patients with PC. The calculation of costs was based on drugs’ priсes from the  List of Vital and Essential Drugs in Moscow region. In addition we made an estimate of the number of extra patients who could have been treated if a less expensive alternative had been applied. One-way sensitivity analysis was made. RESULTS: According to available published data LHRH agonists have similar clinical efficacy and safety that allowed us to use cost-minimization method. Costs for the medications in a hypothetical cohort of 100 patients with PC were equal to 290.263; 332.690 and 391.595 USD per year for L, G and T respectively. When L is used instead of G and T extra 14 and 34 patients can be treated with LHRH for 1 year respectively. Sensitivity analysis has shown, that L is  less expensive if its price is no more than +14,6 % and +34,91%  from baseline when compared to G and T respectively. CONCLUSIONS: L-based therapy has equal clinical efficacy comparing to the other LHRH analogues and is on average a cost saving option when compared with G and T.